You are here

Article Text

Article menu
Download PDFPDF
Aetiology
Cohort study
Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study
  1. Ryan D Madanick
  1. Division of Gastroenterology & Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
  1. Correspondence to : Dr Ryan D Madanick
    Division of Gastroenterology & Hepatology, University of North Carolina School of Medicine, CB# 7080, Chapel Hill, NC 27599, USA; madanick{at}med.unc.edu

http://dx.doi.org/10.1136/eb-2012-101107

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Targownik LE, Leslie WD, Davison KS, et al. the CaMos Research Group. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012; 107: 1361– 9.OpenUrlCrossRefPubMed

    Context

    Proton pump inhibitors (PPIs) are among the most widely prescribed drug classes worldwide. However recent studies have raised concerns about side effects associated with their long-term use. One major concern related to their use is the development of hip and vertebral fractures, although the relationship remains highly controversial. The mechanism through which PPIs could increase fracture risk is not established, although the speculation is that osteoporosis could develop via PPI-induced alterations in calcium metabolism. This study aimed to evaluate the association between PPI use and decline in bone mineral density (BMD) over time.

    Methods

    This study used data from the Canadian Multicentre Osteoporosis Study (CaMos), which consisted of a population-based stratified random sample of the …

    View Full Text

    Footnotes

    • Funding The project described was supported in part by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1RR025747. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

    • Competing interests RDM has delivered educational presentations and lectures for AstraZeneca until May 2011.